Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study with 3 dose
levels of IMO-2125 in combination with standard weight based ribavirin (investigational
treatment arm) or placebo in combination with ribavirin (RBV). Each cohort of 15 patients
will be randomized 4:1 to receive the investigational treatment arm (12 patients) or placebo
and RBV arm (3 patients).